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Abstract. Melatonin, synthesized in and released from the 
pineal gland, has been demonstrated by multiple in vivo and 
in vitro studies to have an oncostatic role in hormone-dependent 
tumors. Furthermore, several clinical trials point to melatonin 
as a promising adjuvant molecule to be considered for cancer 
treatment. In the past few years, evidence of a broader spectrum 
of action of melatonin as an antitumor agent has arisen; thus, 
melatonin appears to also have therapeutic effects in several 
types of hormone-independent cancer, including ovarian, 
leukemic, pancreatic, gastric and non-small cell lung carcinoma. 
In the present study, the latest findings regarding melatonin 
molecular actions when concomitantly administered with 
either radiotherapy or chemotherapy in cancer were reviewed, 
with a particular focus on hormone-dependent breast cancer. 
Finally, the present study discusses which direction should be 
followed in the next years to definitely clarify whether or not 
melatonin administration could protect against non-desirable 
effects (such as altered gene expression and post-translational 
protein modifications) caused by chemotherapy or radiotherapy 
treatments. As treatments move towards personalized medi-
cine, comparative gene expression profiling with and without 
melatonin may be a powerful tool to better understand the 
antitumor effects of melatonin, the pineal gland hormone.
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1. Introduction: Chemotherapy for breast cancer
According to the World Cancer Research Fund International, 
breast cancer is the most frequent type of tumor suffered 
by women in the world, with ~1.7 million newly diagnosed 
cases in 2012 (1). Approximately 1 in 8 women will develop 
a mammary tumor during her lifetime. The American Cancer 
Society's report for the USA in 2015 informs of 231,840 new 
cases of invasive breast cancer, 60,290 women with carci-
noma in situ and ~40,290 mortalities (2). In addition, breast 
cancer is the second cause of mortality by cancer in women, 
only exceeded by lung tumors (3). The mortality rates for 
breast cancer have been declining since 1989, particularly in 
premenopausal women, probably as a result of earlier detec-
tion as well as improved treatments (4). One fact that may also 
explain this decrease is the less frequent administration of 
hormone replacement therapy (HRT) following the publication 
of a report (the Women's Health Initiative) published in 2002, 
which suggests that HRT may be a risk factor that could 
explain the increase in the incidence of breast cancer (5).
Chemotherapy consists of treatment with cancer-killing 
drugs administered either intravenously or orally. 
Chemotherapy compounds are usually applied by intravenous 
infusion and, through the bloodstream, they reach growing 
cancer cells in almost all body tissues. Chemotherapy 
compounds work by targeting cells with a high rate of 
self-renewal, which is a hallmark of cancer cells (6). 
Chemotherapy is recommended following surgery (adjuvant 
chemotherapy): Surgery is performed to dissect the tumor, 
and adjuvant therapy is administered to try to eliminate any 
cancer cells that had not been removed by the surgery and 
may spread out later (7). The most frequently used adjuvant 
treatments to be administered subsequent to surgery are radia-
tion, chemotherapy, targeted therapy and hormone therapy (8). 
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Neoadjuvant therapy refers to treatments that are administered 
prior to surgery instead of subsequent to surgery. The benefits 
of neoadjuvant chemotherapy are that drugs may cause a 
decrease in the size of the tumor, thus facilitating tumor 
removal with a less extensive surgery (9). In addition, admin-
istering chemotherapy prior to the tumor being removed may 
aid the subsequent monitoring of the disease, since in case the 
first cocktail of drugs does not diminish the tumor size, other 
compounds may be considered (10). Finally, chemotherapy 
is also employed as a treatment strategy for patients whose 
tumor has spread outside the mammary gland and underarm 
area. Combinations of drugs are commonly used to treat 
mammary tumors detected in the early stages of carcinogen-
esis, while advanced cancer is more commonly treated with 
a unique chemotherapeutic molecule (11). Chemotherapy is 
usually administered in cycles, with periods of administration 
followed by resting periods to allow patient recovery and to 
minimize the side effects of treatment (12).
Since microtubules participate in the migration of 
chromosomes to opposite ends of mitotic cells during the 
anaphase, microtubule inhibitors (MIs), also known as micro-
tubule-stabilizing agents, are molecules suitable to use in the 
treatment of mammary tumors. MI agents include microtubule 
depolymerizing compounds (Vinca alkaloids) and polymer-
izing agents (taxanes) (13). Vinca alkaloids derive from the 
periwinkle plant Catharanthus roseus (14). The first clinical 
trial demonstrating their efficacy in cancer was reported 
in 1963 (15). Nowadays, these compounds are produced 
synthetically and include vinblastine, vincristine, vindesine 
and vinorelbine (14). The main mechanism that explains their 
cytotoxicity is their capability to interfere with tubulin, with 
subsequent microtubule function disruption (particularly 
concerning microtubules implicated in the formation of 
the mitotic spindle apparatus), leading to mitosis disruption 
and finally resulting in metaphase arrest (16). These agents 
interfere with the assembly of tubulin by introducing a wedge 
between the contact surfaces of two tubulin molecules (17).
Taxanes are diterpenes obtained from Taxus brevifolia (18). 
The first reported taxane, named taxol, was initially isolated in 
1971 (19). Taxanes present difficulties in formulation because 
they are poorly soluble in water, and for this reason, the first 
clinical trial including taxanes was not reported until 1987 (20). 
The other taxane currently in use is docetaxel, which is obtained 
from Taxus baccata (21). Both paclitaxel and docetaxel act 
as spindle poisons, stabilising the tubulin polymers against 
depolymerisation. In addition, they also promote microtubulin 
assembly. These two actions together block microtubule 
dynamics and consequently lead to cell cycle arrest (22). 
Taxanes induce changes in tubulin spatial conformation, which 
interferes with the depolymerisation of microtubules in a 
precise directional way, by binding a specific domain of tubulin 
located in the internal surface of the microtubule (23,24).
Anthracyclines such as epirubicin and doxorubicin are 
also commonly used in chemotherapy combined with other 
chemotherapeutic drugs to treat breast cancer in patients who 
have had surgery to remove the tumor (25). Their mechanism 
of action is based on their ability of insertion between two 
DNA strands, resulting in a DNA-anthracycline complex that 
inhibits both DNA and RNA synthesis (26). This mechanism 
also targets DNA for cleavage by topoisomerase II, which leads 
to a cellular cascade that eventually results in cell death (27). 
Epirubicin is frequently selected over doxorubicin in numerous 
chemotherapy protocols, since it appears to have fewer side 
effects (28). Eribulin is a new anthracycline approved by the 
Food and Drug Administration of USA in 2010 to treat women 
with metastatic tumors who had been previously treated with 
at least two chemotherapeutic compounds indicated for the 
treatment of metastatic breast cancer (29). This drug exerts 
its anticancer effects by triggering a mitotic blockade, leading 
cancer cells to enter apoptosis (30).
Other current approaches in the treatment of breast cancer 
include compounds developed against specific identified 
targets (molecular‑targeted therapies) that contribute to tumor 
growth (31). As an example, trastuzumab is a monoclonal antibody 
used to treat patients with metastatic breast cancer. Trastuzumab 
is indicated against tumors overexpressing the oncogene human 
epidermal growth factor receptor 2 (HER2)/neu, since it targets 
the membrane HER2/neu receptor, which normally promotes 
normal cell growth and is also overexpressed in certain cancerous 
breast tissues (32). Despite several randomized clinical trials with 
promising results (33), other reports indicated that both de novo 
and acquired resistance to trastuzumab could be developed (34). 
Therefore, other recently described agents have been included 
in the list of chemicals available to treat HER2-overexpressing 
mammary tumors. One of them is lapatinib, a reversible inhibitor 
of both epidermal growth factor receptor (EGFR) and HER2/neu 
tyrosine protein-kinases (35), which was approved in 2007 for 
women undergoing metastatic breast cancer with acquired 
resistance to trastuzumab (36). Lapatinib was well tolerated and 
displayed encouraging clinical results when used as a first‑line 
therapy agent in ErbB2‑amplified tumors, either advanced local 
tumors or metastatic breast cancer (37). Another molecule to be 
considered is HKI‑272, a (Her2)/neu receptor tyrosine kinase 
inhibitor with an irreversible mechanism of inactivation and a 
demonstrated clinical activity, which is well tolerated among 
both high-dose trastuzumab pre-treated and non pre-treated 
patients with advanced ErbB2-positive mammary tumors (38). 
HKI-272 targets a cysteine residue located in the adenosine 
triphosphate-binding pocket of the ERbB2 receptor, resulting 
in the inhibition of the downstream signal transduction cascade 
triggered, and consequently altering the cell cycle regulation (39).
Among the battery of promising new chemicals, drugs that 
target heat shock protein (Hsp) 90 must be mentioned. Hsp90 
belongs to the family of chaperones and establishes associations 
with a set of different proteins that are known as ‘Hsp90 client 
proteins’ (40). Multiple Hsp90 client proteins are implicated 
in breast tumor progression and resistance to chemotherapy 
treatments, including the receptor protein-tyrosine kinases of 
the ErbB2 family, estrogen receptor (ER), Akt and mutated 
versions of p53 (41). The efficacy of Hsp90 inhibitors has been 
well documented in several preclinical cancer models. One 
of these inhibitors is 17-AAG, which has completed phase I 
testing (42,43).
Angiogenesis is a physiological process that consists 
in new vessel formation. When a tumorous mass of cells is 
growing, angiogenesis is crucial to maintain both tumor 
growth and progression (44). Therefore, numerous drugs have 
been tested during the past decades in the hope of identifying 
specific inhibitors of the different pathways necessary for 
angiogenesis (45). One of the key molecules in the formation 

























































































































of new vessels is vascular endothelial growth factor (VEGF), 
probably the most studied angiogenic factor (46). VEGF is 
implicated in the progression of breast cancer and is also a 
potential prognosis biomarker (47). Bevacizumab (Avastin®) 
is a recombinant humanized monoclonal antibody that 
recognises all the known variants of VEGF-A (48). To date, 
bevacizumab is the unique anti-angiogenic chemical with 
clearly demonstrated benefits in metastatic breast cancer 
treatment clinical trials (49,50). Pazopanib is another inhibitor 
of VEGF receptor (VEGR) (51). Pazopanib also inhibits the 
signaling pathways downstream of the platelet-derived growth 
factor receptor and the mast/stem cell growth factor receptor 
c-KIT (52). Pazopanib treatment provides disease stability in 
patients with advanced breast cancer (53).
Estrogens are implicated in the development of the mammary 
gland, and are also known to be key stimulators of both the 
genesis and growth of mammary tumors (54). Therefore, one of 
the main strategies to fight breast cancer is neutralizing the stim-
ulating actions of estrogens on the mammary gland (55). Several 
chemicals have been tested and commercialized, since they are 
selective inhibitors of the effects of estradiol on the breast. These 
include selective estrogen receptor modulators (SERMs), which 
are chemicals that directly bind to ER, thus inhibiting its actions 
by interfering with the binding of endogenous estrogens (56). Of 
these, tamoxifen (57,58) and a number of its derivatives (56) are 
the best known examples. Fulvestrant is an ER antagonist that 
has no agonist effect described and downregulates the protein 
levels of ERα (59). Fulvestrant is being currently administered 
to postmenopausal women with advanced breast cancer whose 
tumors are ER positive and have progressed upon receiving 
first‑line endocrine therapy (60). Other compounds developed 
against estrogens are chemicals that prevent the production 
of steroids by downregulating the enzymes necessary for the 
conversion into estradiol from androgenic precursors. These 
drugs belong to the class known as selective estrogen enzyme 
modulators (SEEMs), which include both steroidal (such as 
formestane or exemestane) and non‑steroidal (such as anastro-
zole and letrozole) compounds (61).
2. Melatonin and mammary cancer: In vitro and animal 
studies
Melatonin is an indolic hormone produced principally by the 
pineal gland. Melatonin is a ubiquitously distributed molecule 
with a variety of diverse functions (62). Melatonin employs 
a diverse set of mechanisms to regulate the physiology and 
molecular biology of cells (63). The majority of actions of mela-
tonin are based on its ability to bind to melatonin membrane 
receptors, which are G-protein coupled receptors that trigger 
cellular signaling pathways (64). The pineal hormone also acts 
through orphan receptors or molecules such as calmodulin (65). 
Additionally, melatonin can detoxify free radicals and related 
oxygen derivatives via receptor-independent pathways (66).
Concerning tumorigenesis, numerous studies have been 
performed in animal models. Experimental approaches include 
increasing the activity of pinealocytes and administering 
exogenous melatonin, which cause a decrease in the number, 
incidence and development of chemically-induced mammary 
tumors (67). However, reduced levels of melatonin (for example, 
by removing the pineal gland) appear to stimulate breast 
cancer progression (68). Several reports established a lower 
cancer risk among totally blind women (69-71). By contrary, 
a moderate but significant increase in the risk of developing 
breast cancer among women who have been working for long 
periods in rotating night shifts (which implicates that they 
were exposed to light during the night, and consequently, the 
nocturnal melatonin production was inhibited) has also been 
documented (72).
The antiproliferative effects of melatonin on the breast 
cancer cell line MCF-7 have been studied for more than two 
decades (73). The data available suggest that the inhibitory 
action of melatonin on mammary cancer estrogen-positive 
cell lines is based on its ability to regulate either the synthesis 
of estrogens or estrogen signaling pathways (74). Thus, the 
pineal hormone is capable of downregulating both the expres-
sion and activity of the enzymes necessary for the synthesis 
of estrogens from androgenic precursors, therefore acting as 
a SEEM. In the MCF-7 cell line, melatonin at physiological 
concentrations exhibits anti-aromatase properties (75). The 
pineal hormone is able to reduce the activity of aromatase, the 
principal enzyme in estrogen biosynthesis. Melatonin inhibits 
aromatase under basal conditions or when the enzyme activity 
is stimulated by cyclic adenosine monophosphate (cAMP) or 
cortisol (76). When gene expression was evaluated and the 
CYP19 gene (coding for aromatase) was examined, it was 
observed that melatonin downregulated its expression at the 
transcriptional level (76). The major bloodstream circulating 
form of physiologically inactive estrogen is estrone sulfate, 
which acts as an estrogen reserve (77). The enzyme steroid 
sulfatase (STS) converts inactive estrogen sulfates into estrone 
and estradiol. Estrone can be further transformed into physi-
ologically active estrogen by the action of 17β-hydroxysteroid 
dehydrogenase type 1 (17β‑HSD1). Finally, the enzyme 
estrogen sulfotransferase (EST) sulfonates estrogens to form 
biologically inactive estrogen sulfates. Both enzymes, STS 
and EST, serve a role in the modulation of the in situ levels of 
estradiol in hormone-dependent tumors (78). Melatonin modu-
lates the expression and activity of aromatase, STS, 17β-HSD1 
and EST not only in tumor cells, but also in surrounding cells 
such as fibroblasts and endothelial cells (74,79-82).
Melatonin can also counteract the different actions of estro-
gens, thus functioning as a naturally occurring SERM (83). The 
mechanisms implicated in the antiestrogenic effects of melatonin 
are yet being elucidated. Unlike other antiestrogenic molecules 
such as tamoxifen, melatonin does not directly bind to ER (84). 
In estrogen-positive breast cancer cells, melatonin decrease 
the expression of ERα (85) and impairs the estrogen‑mediated 
transcriptional activation of genes through destabilization of 
the estradiol-ER complex, preventing its binding to DNA in 
both estrogen response element (ERE)‑ and activator protein 
1-containing promoters (86). This effect appears to be mediated 
by calmodulin, since melatonin behaves as a calmodulin antag-
onist. The pineal hormone promotes structural changes in the 
calmodulin-ERα protein complex, thus facilitating its binding 
to an ERE (87,88). Remarkably, melatonin does not alter the 
recruitment of co-activators triggered by ERα, suggesting that 
melatonin mechanisms of action diverge from those of other 
anti-estrogen chemicals used in breast cancer treatment (88). 
It is important to mention that only ERα, but not ERβ, binds 
to calmodulin (84). The substitution for glycine of two lysine 

























































































































residues located at positions 302 and 303 of the hinge domain 
of ERα generated a mutant version of ERα that was incapable 
of binding to calmodulin, and that therefore turned into a mela-
tonin non-regulated receptor (88). The effects of melatonin may 
also be explained in terms of binding to its specific membrane 
receptors, such as melatonin receptor type 1 (MT1), resulting 
in an interplay with the ER signaling pathway (89). MT1 
receptors are present in normal human breast tissues and in 
tumor tissues (90). Melatonin and estradiol signaling pathways 
converge and they have opposite effects over cAMP intracel-
lular concentrations. In breast cancer cells, estrogens trigger 
adenylate cyclase activation, which results in increased cAMP 
cytoplasmic levels in a classical short-time second-messenger 
mechanism that is independent of transcription (91). The 
increase in cAMP levels cooperates with long-time genomic 
effects of estradiol, thus enhancing ER-mediated transcriptional 
activation (91). By contrary, melatonin, through its specific 
binding to its membrane receptor MT1, inactivates adenylate 
cyclase, resulting in decreased cAMP levels (92).
The fact that only those human mammary cancer cell 
lines that are ERα+ are sensitive to the antimitotic actions of 
melatonin supports the theory that the antitumor effects of 
this indolamine occur through its actions on breast cancer 
cells' estrogen-responsive pathways (93). Melatonin is able 
to block, under different culture conditions, the mitogenic 
effects of estradiol (94). The antiproliferative effect of this 
indolamine could be explained through the modification of 
the levels of estrogen-modulated proteins, several growth 
factors and proto-oncogenes such as c MYC, transforming 
growth factor (TGF)α, Trefoil factor 1, also known as pS2, 
progesterone receptor (PGR), AP1 transcription factor subunit 
c-fos and TGFβ in human estrogen-positive breast cancer 
cell lines (94,95). Estradiol enhances cell proliferation and 
provokes cell cycle progression (96). The inhibitory effect of 
melatonin (as occurs for tamoxifen) on cell proliferation is 
cell‑cycle specific, causing the presence of melatonin a delay in 
the G1-S transition (97). Changes in cell‑cycle timing typically 
implicate modifications in various key proteins that regulate 
the process. The inhibitory action of the pineal hormone on 
cell cycle progression can be interpreted through its effects 
on the expression of certain proteins controlling the G1-S 
cell cycle transition. Thus, several studies have demonstrated 
that melatonin increases the expression of p53 and p21Waf1 in 
experiments performed in vitro (98,99). The upregulation of 
these proteins may be a crucial mechanism explaining how 
melatonin impedes the progression through the cell cycle at 
the G1-S transition. The accumulation of cells in G1 forces 
them to enter G0, causing the cancer cells to undergo a higher 
differentiation, since G0 is characterized to be a quiescent 
state (100). This suggest that the anti‑estrogenic, oncostatic 
and antiproliferative effects of melatonin on human mammary 
cancer estrogen-positive cell lines may be explained, at least 
in part, by the ability of the pineal hormone to inhibit cell 
proliferation at the same time that it enhances cell differen-
tiation. Furthermore, several studies have demonstrated that 
melatonin inhibits human telomerase reverse transcriptase, 
which is the rate-limiting factor conditioning the telomerase 
activity in breast cancer cells (101,102).
Another effect of melatonin in MCF-7 cells is its 
ability to reduce their invasiveness (103,104). Melatonin 
treatment decreases the attachment of the cells to the base-
ment membrane (105). The pineal hormone reduces the 
chemotactic response of MCF-7 cells (105). Melatonin also 
blocks the cell migration and invasion that occurs in response 
to estradiol (105). Cancer cells' motility and invasion are 
known for being adhesion-dependent mechanisms that 
require the expression of cell-surface molecules necessary for 
adhesion (106). In tumor progression, downregulation or loss 
of expression of several of these surface-adhesion proteins 
frequently happens, which leads to the loss of cell-cell 
recognition and the acquisition of an invasive phenotype 
by the tumor cells; these events correlate with poor cell 
differentiation (107). All the factors mentioned above are 
associated with poor prognosis in cancer progression (108). 
Importantly, among the melatonin antitumor actions, it has 
been reported that melatonin induces the expression of both 
β1-integrin and E-cadherin, two main proteins essential for 
cell-cell and cell-matrix interactions; thus, melatonin changes 
estrogen-responsive tumor cells into a less invasive phenotype 
by inducing their differentiation (105).
Finally, melatonin exerts its modulatory effect in the 
tumor microenvironment by controlling the production and 
secretion of several cytokines. These cytokines are produced 
by breast cancer cells and regulate the differentiation of the 
fibroblasts located in close proximity to malignant epithelial 
cells. Additionally, it has been demonstrated that cytokines 
produced by malignant cells stimulate the aromatase expres-
sion and activity in these fibroblasts (109,110) and in proximal 
endothelial cells (111). VEGF is a growth factor that serves 
an essential role in angiogenesis. VEGF is produced and 
secreted by malignant epithelial cells and recognizes VEGFRs 
located in the cell surface of endothelial cells. The binding of 
VEGF to its receptor triggers a cascade of intracellular events 
that stimulate endothelial cells to undergo proliferation and 
migration (112,113). Therefore, pharmacological agents able 
to inhibit the production of this pro-angiogenic factor are of 
great interest, and could serve an essential role in impairing 
both tumor angiogenesis and tumor growth. Melatonin may 
be one molecule to consider, since it can regulate the para-
crine mechanisms connecting tumor epithelial cells and the 
surrounding endothelial cells. One of the main actions of 
the pineal hormone is that melatonin treatment results in the 
downregulation of VEGF expression in estrogen-responsive 
breast cancer cells. As a result, the VEGF levels available for 
receptors expressed in endothelial cells are lower, and there-
fore, the number of cells producing estrogens in the proximity 
of the malignant cells is reduced. Reduced estrogen levels and 
a lower capability of formation of new vessels as a result of 
the presence of melatonin will diminish the tumor ability to 
spread and grow (114).
In summary, a unique molecule, melatonin, has anti-estro-
genic properties: It selectively counterbalances the actions 
of estrogens in both normal and tumor breast tissues, and 
provides a novel strategy to reduce the local biosynthesis of 
estrogens from androgens (which in turn, is one of the principal 
objectives of antitumor pharmacological therapy) (115). These 
cumulative actions of the pineal hormone point to its potential 
application as an anticancer molecule in both the prevention 
and treatment of estrogen-positive tumors, since, as it has 
been pointed above, this molecule acts at different levels by 

























































































































interfering with estradiol-dependent signaling pathways, both 
in tumor cells and in the surrounding endothelial cells and 
fibroblasts (116).
3. Melatonin and cancer: Clinical trials
As aforementioned, numerous experiments performed in vitro 
(breast cancer cell lines such as MCF‑7) and in vivo (animal 
models) have well established the oncostatic properties of 
melatonin (117). Since melatonin plasma levels are diminished 
in estrogen-dependent breast cancer patients, various clinical 
trials have been performed to evaluate the potential beneficial 
effects of melatonin in human neoplasms. Following the pioneer 
clinical work of Lissoni et al (118), who evaluated the effect of 
melatonin in cancer patients bearing untreatable advanced solid 
tumors, multiple studies have been performed and published to 
date (119). However, the value of melatonin as an adjuvant agent 
in cancer treatment is not totally clear, and consensus about 
positive melatonin actions appears to be difficult to achieve. 
A number of studies point to melatonin as a treatment with no 
beneficial effects. In cachectic patients with gastrointestinal or 
advanced lung cancer, including a dose of melatonin at night 
did not improve parameters such as appetite, weight or quality 
of life of patients, in comparison with patients who received 
a placebo (120). In patients with brain metastases, high doses 
of melatonin did not produce any beneficial effect (121). By 
contrast, there are a large number of reports supporting the 
potential benefits of melatonin if included in chemotherapy 
protocols. In breast, lung and gastrointestinal cancer patients, 
melatonin protected against thrombocytopenia, and stomatitis, 
asthenia and neuropathy were less recurrent in the group of 
melatonin-treated patients (122). It has also been reported that 
melatonin offers certain protection to hematopoietic progeni-
tors from the toxic actions of anticancer chemotherapeutic 
chemicals; thus, melatonin has been reported to attenuate the 
damage to precursor blood cells caused by both radiotherapy 
and chemotherapy treatments (123). It has also been suggested 
that melatonin may protect patients against side effects such as 
asthenia, cardiotoxicity and neurotoxicity caused by chemo-
therapy (124). Additionally, the pineal hormone increases the 
1-year survival and tumor regression rates in cancer patients 
with metastatic solid tumors with poor clinical status (125). 
In metastatic non-small cell lung cancer patients treated either 
with just chemotherapeutic agents or with chemotherapy plus 
melatonin, both the overall tumor regression rate and the 5-year 
survival rate of patients concomitantly receiving melatonin 
were significantly higher as compared with those receiving 
only chemotherapeutic agents. It appears that chemotherapy 
was better tolerated in patients who also received the pineal 
hormone (126). The study points to melatonin as an adjuvant 
drug capable of improving the effectiveness of chemotherapy 
in terms of both quality of life and survival of patients (126). A 
recent report concludes that melatonin combined with chemo-
therapy did not significantly improved survival or ameliorated 
various adverse side effects in patients with non-small cell lung 
advanced cancer, although certain improvement in the quality 
of life of these patients was observed (127). A systematic 
review comprising data from 21 clinical trials (all the patients 
enrolled in the studies were bearing solid tumors), in which the 
effect of melatonin concomitantly added in conjunction with 
chemotherapy or radiotherapy was evaluated, and supportive 
care, partial response, complete response, 1-year survival 
and chemotherapy-associated toxicities were assessed (128), 
concluded that melatonin may serve a beneficial role in cancer 
patients who are treated with chemotherapy. Patients who 
received melatonin experienced substantial improvements, 
particularly in terms of tumor remission and 1-year survival 
rates and melatonin also ameliorated the side effects of 
chemotherapy (127,128). Furthermore, another review summa-
rising the data from eight eligible randomized controlled trials 
(n=761) obtained similar conclusions (129).
4. Can melatonin enhance the beneficial and protect 
against the deleterious effects of chemotherapy?
As aforementioned, it is well documented that melatonin 
diminishes the incidence of chemically induced cancers and is 
able to slow down the growth of certain hormone-responsive 
cancers (67,117). The antitumor actions of this indolamine 
have been described in breast cancer, both in in vivo animal 
experiments (in 7,12-dimethylbenz[a]anthracene chemically 
induced mammary tumors in rodents) and in in vitro assays 
(in estrogen‑positive human mammary cancer cell lines) (64). 
Furthermore, there are numerous reports endorsing the 
beneficial use of melatonin during chemotherapy in clinical 
trials (118,122-124). Therefore, the ultimate goal of the 
present review is to provide a compilation on the current 
knowledge concerning the interplay of melatonin and chemo-
therapy agents at the molecular level. The PubMed database 
(www.ncbi.nlm.nih.gov/pubmed) was interrogated for cita-
tions of 84 genes known to be commonly involved in the 
dysregulation of several normal processes during breast 
carcinogenesis, which are also present in breast cancer 
cell lines. The list includes signal transduction genes and 
other genes involved in usually altered pathways, including 
cellular adhesion, angiogenesis, proteolytic activities, cell 
cycle progression, cell cycle control and apoptosis (Table I). 
Research into carcinogenic mechanisms (130) has identified 
during the last decades numerous functional alterations due 
to somatic mutations, gene expression alterations and altered 
post-translational protein modifications (131). Therefore, 
the database search was performed including as keywords 
i) the name of each gene, ii) breast cancer, iii) melatonin, and 
iv) chemotherapy.
For the majority of genes reviewed, there were thousands 
of citations in the literature when the search included the name 
of each gene and breast cancer as key words. When melatonin 
was included in the selection criteria, the number of articles 
was markedly reduced; thus, 53 out of the 84 genes surveyed 
did not have a single report associated under these criteria. 
Searching for ER together with melatonin and breast cancer 
led to ~100 articles, whereas p53 and PGR searches produced 
15 and 12 reports respectively, and the rest of the 28 genes 
evaluated produced 1-9 articles.
The number of reports was further reduced if chemo-
therapy was also included in the selection criteria. Only 25 of 
the 84 genes assessed are included in the list (Table I), indi-
cating that, for 59 out of 84 genes, there is not a single study 
published including the gene name, melatonin, breast cancer 
and chemotherapy as keywords.

























































































































In Table II, a search was performed including as keywords 
melatonin (20,724 articles) melatonin and breast cancer 
(524 articles), and 28 drugs commonly used as chemotherapy 
in breast cancer treatment (6,9). Apart from tamoxifen 
(23 articles fulfilled the criteria ‘melatonin, breast cancer 
and tamoxifen’), the results show that there is limited infor-
mation at the molecular level concerning the implication of 
co-treatment with the pineal indolamine and chemotherapy 
agents in breast cancer targeted therapy, and no report was 
available for 13 of the 28 drugs searched. In conclusion, 
despite the fact that during decades numerous articles have 
reported experimental data from in vitro and in vivo experi-
ments showing the oncostatic actions of melatonin, the present 
review demonstrated that there are limited reports studying 
the effects of melatonin and chemotherapy agents in combina-
tion in cancer treatments, and particularly, in breast cancer. 
Similarly, little is known about the role of melatonin regarding 
the expression and functionality of the genes reported to be 
altered in cancer, particularly in breast cancer. There is little 
information available nowadays about gene expression profiles 
in all types of cancer, and particularly in estrogen-responsive 
breast tumors. There is also limited information available on 
how the gene expression profile may be altered by treatment 
with different chemotherapeutic compounds and, remark-
ably, whether or not melatonin has protective effects when 
administered together with chemotherapeutic agents. The 
majority of information available about melatonin, cancer, 
chemotherapy, and altered gene expression and function has 
been published (132,133) in the last few years (Fig. 1). This 
indicates that nowadays there is a growing field of research 
about this topic. Several of the most relevant findings recently 
reported with regard to the modulatory role of melatonin in 
cancer at the molecular level include the circadian interruption 
of melatonin production by exposure to light at night, which 
results in the development of resistance to tamoxifen treatment 
in breast cancer patients (134). In this context, it has also been 
described how nocturnal disruption of melatonin plasma levels 
originates a complete loss of tumor response to the chemo-
therapeutic agent doxorubicin (135). The resistance of cancer 
cells to chemotherapy treatments such as doxorubicin usually 
implicates an upregulation of P-glycoprotein, which is respon-
sible for drug efflux from cells (136). In this context, there is 
a report describing that melatonin treatment increases doxo-
rubicin intracellular concentrations in cancer cells, suggesting 
that melatonin may inhibit P-glycoprotein (137). In breast 
cancer xenografts implanted in animal models (nude mice), 
treatment with the pineal hormone stopped the tumor progres-
sion by reducing tumor size and cell proliferation (Ki‑67), as 
well as by inhibiting angiogenesis (138). Melatonin treatment 
results in increased expression of Bcl‑2‑like protein 11 (Bim) 
parallel to lower levels of cyclooxygenase (COX)‑2, which in 
turns potentiate tunicamycin-induced apoptosis in mammary 
cancer cells (139). Regulation of the COX‑2, Akt, p300 and 
apoptotic protease activating factor-1 signaling pathways by 
melatonin inhibits cell proliferation and triggers apoptosis in 
breast cancer cells in in vitro models (140). Melatonin also 
regulates mouse double minute 2 homolog (MDM2), since this 
indolamine strongly represses MDM2 gene expression and 
inhibits MDM2 translocation into the nucleus of the cells (141). 
This can be explained because melatonin stimulates ribosomal 
protein L11 and inhibits the phosphorylation of MDM2 by 
Akt-phosphatidylinositol-4,5-bisphosphate 3-kinase (141). 
Melatonin downregulates sirtuin, which is a specific inhibitor 
of p300, and upregulates p300 and murine double minute X 
(MDMX) (141). As a consequence, cells exposed to mela-
tonin exhibit significantly increased levels of p53 and of its 
acetylated form (141). Finally, there is a significant increase 
in p21 levels in melatonin-treated tumor cells (141). It has 
been reported that melatonin sensitizes non-small cell lung 
cancer cells harboring a mutated form of EGFR to gefitinib 
(a tyrosine kinase inhibitor) (142). In combination with 
cisplatin, melatonin enhances the cytotoxic effects of this 
chemotherapeutic agent and promotes the entry into apoptosis 
of lung cancer cells (143) and cervical cancer‑derived HeLa 
cells (144). Consistently with these findings, co‑treatment 
with melatonin and each of the following three chemotherapy 
agents: Cisplatin, 5‑fluorouracil and doxorubicin, resulted in 
an enhancement of cytotoxicity and apoptosis triggered by 
chemotherapy in the cell line AR42J, which is derived from rat 
pancreatic tumors (145). There is only one report addressing 
the effect of melatonin combined with the purine nucleoside 
antimetabolite clofarabine, describing that melatonin use as 
co-treatment led to an enhanced cytotoxic effect of clofara-
bine in leukemic cell lines, which was associated with higher 
levels of acetylation (146). In ER+ breast cancer rat models 
treated with Adriamycin®, melatonin co-treatment results in 
lighter tumor weights, increased tumor cell apoptosis, higher 
expression of E-cadherin and higher survival rate (147). In 
combination with the nucleoside analogue gemcitabine, recent 
reports demonstrate that melatonin inhibits both prolifera-
tion and invasion of pancreatic ductal adenocarcinoma cells 
through nuclear factor-κB inhibition (148). Melatonin supports 
the effects of doxorubicin by activating transient receptor 
potential vanilloid 1 and apoptosis, thus inducing MCF-7 
cell death (149). In a model of ovarian carcinoma, melatonin 
therapy promotes apoptosis along with the upregulation of 
p53, B‑cell lymphoma (Bcl)‑2‑associated X protein (Bax) 
and cleaved caspase-3, suggesting that melatonin triggers 
apoptosis in ovarian cancer cells (150). In a gastric cancer cell 
line (AGS), p38, c‑Jun N‑terminal kinase and extracellular 
signal-regulated kinase were activated by melatonin, which 
also significantly increased caspase‑3 activity, increased the 
expression of the pro-apoptotic gene Bax and decreased the 
expression of the anti-apoptotic gene Bcl-2 (151). Additionally, 
melatonin is able to strengthen the antitumor effects of 
cisplatin with low systemic toxicity (143).
5. Conclusions
Melatonin is a notable molecule to be considered in cancer 
treatment. A growing amount of evidence in the last few years 
has suggested that melatonin behaves as an oncostatic agent 
in a variety of cancer types in general, an in particularly, in 
hormone-dependent breast cancer, as documented from 
numerous studies performed either in animal models in vivo or in 
cell lines derived from human breast cancer in vitro (64,67,81). 
Clinical trials suggest that melatonin can have protective 
effects when administered along with chemotherapy in patients 
suffering from advanced solid tumors (129). The mechanisms 
underlying the oncostatic actions of the pineal hormone in 

























































































































estrogen-dependent breast tumors are based on its behaviour as 
a SERM and SEEM, as well as on the ability of melatonin to 
influence the communication among malignant epithelial cells, 
endothelial cells and fibroblasts in breast cancer (110,116). 
However, to date, there is limited knowledge about the inter-
plays of melatonin and chemotherapy on molecular aspects 
such as gene expression profiles and gene post‑translational 
modifications, which must be further addressed in the future.
6. Melatonin and cancer: What next?
Melatonin is a pleiotropic molecule that exerts numerous 
physiological functions and serves important roles in different 
processes, including circadian rhythm, sleep and reproduc-
tion (152). A particular characteristic of the pineal hormone is 
the diversity of molecular mechanisms that act to regulate the 
above physiological processes. Melatonin reduces cell prolifera-
tion and growth of estrogen-positive breast tumors by interfering 
with estrogen signaling pathways. Data obtained from experi-
ments performed in breast cancer cell lines (93,94) and animal 
models (81,116) have provided evidence that melatonin 
diminishes the incidence of mammary tumors and limits their 
growth in vivo, and inhibits the proliferation of human breast 
cancer cell lines and interferes with their metastatic behaviour 
in vitro (81,97). There are several proposed theories to explain 
the mechanisms by which melatonin reduces the growth and 
Table I. PubMed search results.a
    Gene AND Gene AND 
  Gene  breast breast cancer Gene AND
  AND Gene cancer AND cancer AND
Gene   breast AND AND melatonin AND melatonin AND
name Genea cancer melatonin melatonin chemotherapy chemotherapy
ER   68,885 31,082 189 96 31 52
p53   78,342   7,698   80 15   7 12
p21   31,647   2,174   35   9   5 12
VEGF   57,030   2,737   64 12   3 11
PGR   33,762 13,582   73 96   3   5
TGFB1   22,043      561   25   4   3   4
MYC   29,932   1,882   17   5   3   3
CDH1   23,363   2,200   13   5   3   3
IL6   96,419   1,106 162   3   2 10
GSTP1   35,897      901   91   2   2   7
c-JUN 102,575   2,952 106   6   2   6
RARB   11,545      651   76   9   2   5
CCND1   16,332   2,205   16   6   2   2
AR   22,741   1,690   64   3   1 11
AKT   54,018   3,992   92   6   1 10
Ki‑67   20,827   3,129   18   5   1   5
ERK1   26,166   1,153   61   4   1   3
ERBB2   22,268 14,282   72   3   1   3
EGFR   35,864   3,550    7   3   1   3
IGFBP3     5,003      432    6   2   1   2
EGF   29,673   2,215  24   6   1   2
Rb   19,405   1,017  16   1   1   1
IGF1     2,700     160  15   1   1   1
CDK2     6,054     491    5   1   1   1
p73     2,089     113    1   1   1   1
aA search in PubMed database was performed for 84 genes known to be altered in breast cancer. The numbers refer to the citation found when 
the keywords used were: i) ‘Gene name’; ii) ‘gene name’ AND ‘breast cancer’; iii) ‘gene name’ AND ‘melatonin’; iv) ‘gene name’ AND ‘breast 
cancer’ AND ‘melatonin’; v) ‘gene name’ AND ‘breast cancer’ AND ‘melatonin’ AND ‘chemotherapy’; and vi) ‘gene name’ AND ‘cancer’ 
AND ‘melatonin’ AND ‘chemotherapy’. In the table, only the 25 genes that appear at least in one publication with the criteria ‘gene name’ 
AND ‘breast cancer’ AND ‘melatonin’ AND ‘chemotherapy’ are shown. The genes that have appear in any publication under these criteria of 
search are gelatinase A, PTGS2, Bad, Bcl-2, BIRC5, gelatinase B, CTNNB1, APC, ASC, ATM, ABCB1, ABCG2, BRCA1, TFF3, cathepsin, 
µ-PA, SRC, PAI-1, serpine 1, JNK1, IGF1R, CDKN2A, ADAM23, PTEN, NOTCH1, THBS1, ID1, keratin 5, GATA3. ERK2, CCNE1, XBP1, 
NR3C1, BRCA2, MUC1, MLH1, keratin 19, NME1, TWIST1, FOXA1, RASFF1, HIC1, SFN, MGMT, CCND2, cystatin, GRB7, keratin8, 
GLI1, keratin18, SFRP1, SNAI2, p57, cyclin A1, CDH13, CSF1, SLIT2, SLC39A6 and PRM2.

























































































































development of tumors: i) Through an indirect mechanism, by 
downregulating the synthesis of estrogens via downregulation 
of the hypothalamic‑pituitary‑reproductive axis; ii) through a 
direct mechanism, by interfering with the activation of estradiol 
receptors at the cancer cell level, thus behaving as a SERM; 
and iii) melatonin can regulate the enzymes necessary for the 
synthesis of estrogens in other tissues, therefore behaving as a 
SEEM (79). It has been recently demonstrated that melatonin 
regulates the paracrine communication that occurs between 
malignant epithelial cancer cells, the surrounding adipose 
tissue (fibroblasts and adipocytes) and endothelial cells, mainly 
through the downregulation of the levels of growth factors and 
cytokines released by breast tumor cells (116). Thus, the effects 
of melatonin also include anti-angiogenic actions.
In summary, previous studies point to melatonin as a 
molecule that has a great potential to be useful as an anticancer 
chemical without producing adverse effects (128). Therefore, 
melatonin should be considered for both the prevention and 
therapy of estrogen-positive mammary tumors. There are, 
in our opinion, numerous noteworthy possibilities for future 
clinical applications of melatonin in several types of cancer, 
including breast cancer.
Recently, the inhibitory effects of melatonin have been 
described not only for estrogen-dependent breast tumors, but 
also for numerous different cancers, including gastric cancer, 
ovarian carcinoma, pancreatic ductal carcinoma, leukemic 
cell lines, cervical cancer and non-small lung carcinoma 
cells (25,137-139,142,143,153). The majority of the results are 
positive, and melatonin has been described as an inhibitor of 
tumor growth under both in vitro and in vivo experimental condi-
tions (64,81,97). The results arisen in the past few years also 
suggest that melatonin, either alone or along with chemotherapy 
in cancer patients diagnosed with advanced solid tumors, helps 
to improve the outcomes of cancer regression and life expectancy 
of the patients (122,128). Additionally, chemotherapies are typi-
cally better tolerated by patients who are simultaneously treated 
with melatonin (125). Following the pioneer clinical study of 
melatonin potential positive effects in untreatable advanced 
cancer patients performed by Lissoni et al (118) several studies 
have been published (124-129). The main limitation is the 
requirement of further studies, including additional randomized 
double-blind controlled trials with much larger sample sizes and 
implicating several international hospital centres, since the data 
available nowadays derive from clinical trials including only a 
few hundred patients (128). Furthermore, it must be considered 
that not all the studies performed to date point to melatonin as 
a molecule that improves life expectancy and ameliorates the 
adverse effects of chemotherapy (120,121). Thus, in patients 
with advanced lung or gastrointestinal cancer, melatonin did 
not exhibit any beneficial effect, and as consequence, the value 
of melatonin as an adjuvant in the treatment of cancer remains 
unclear from these data (120).
One of the main objectives of the present review was to 
summarise the current knowledge regarding the interplay of 
melatonin and chemotherapy. Since the majority of the poten-
tially beneficial effects of melatonin have been described in 
Table II. Number of publications identified in the MEDLINE 
(https://www.ncbi.nlm.nih.gov/pubmed) journal citation 
database (accessed November 2015), when using as search 
term each of the 28 molecules currently used in breast cancer 
research and/or treatment, alone (second column), including 
melatonin (third column) or including melatonin plus breast 
cancer (fourth column) as searching criteria.
   Melatonin
 Drug  AND
Drug name alone Melatonin breast cancer
- - 20,724 524 
Vincristine 27,607 10   0
Eribulin     252   0   0
Paclitaxel 27,688   8   2
Docetaxel 11,691   3   1
Epirubicin   6,131   5   1
Lapatinib   1,807   1   0
Trastuzumab   7,382   2   0
Pazopanib     825   0   0
Bevacizumab 11,697   6   0
Fulvestrant   2,278   5   1
Anastrozole   1,761   1   0
Irosustat       46   0   0
Tanespicin     665   0   0
Cisplatin 59,192 50   4
Gemcitabine 12,035   6   1
Pitavastin     658   3   1
Pravastatin   4,318   1   1
Vinblastine   1,582 14   0
Cyclophos‑phamide 64,488 63   8
Methotrexate 45,411 20   4
Fluorouracil 48,858 18   6
Adryamicin 60,505 74   8
Vinorelbine   3,472   2   0
Mitomycin 18,202   6   0
Capecitabine   4,746   1   0
Mitoxantrone   5,538   5   2
Carboplatin 13,873   4   0
Tamoxifen 25,107 44 23
Figure 1. Number of publications regarding melatonin and cancer (solid line), 
and melatonin, cancer and gene expression (dotted line) published during the 
last two decades.

























































































































estrogen-responsive breast cancer, the present study searched 
information published on 84 genes known to be dysregulated 
during breast carcinogenesis (corresponding to the genes 
included in The Human Breast Cancer RT² Profiler PCR 
array; Qiagen GmbH, Hilden, Germany). These genes encode 
proteins implicated in signal transduction, angiogenesis, 
proteolysis, cell cycle and apoptosis (154).
The present study also reviewed recently published 
articles associating melatonin with chemotherapeutic 
agents (135-137,142-149). The results indicate that, for 53 out 
of the 84 genes evaluated, there are no current data available 
regarding the effect of melatonin alone or in combination 
with chemotherapy, either in in vivo or in in vitro studies. Our 
findings also show that, apart from tamoxifen, there is limited 
information from research performed at the molecular level 
addressing the potential benefits of co‑treatment of melatonin 
with chemotherapeutic agents (155).
In summary, in our opinion, melatonin is an endogenous 
produced hormone with a high potential of being included 
as an effective anticancer molecule in the prevention and 
treatment of, not only hormone-dependent cancers, but also, 
other types of cancer, since its inhibitory effects have been 
demonstrated in gastric, lung, pancreatic and hematopoietic 
cancers (145,148,151,153). However, in the next years, addi-
tional research must be conducted to clarify if melatonin 
administration in combination with chemotherapeutic agents 
may constitute a novel anticancer treatment. In particular, 
future research concerning the role of melatonin as a non-toxic 
and low-cost drug to be considered in breast and other types of 
tumors must be conducted, particularly at the molecular level. 
Systematic screenings addressing the effects of chemotherapy 
on genes known to be altered in different types of cancer, and 
on how melatonin can modulate the expression and activity of 
those genes, either when acting alone or in combination with 
chemotherapy, should be performed. Once larger clinical trials 
and additional molecular studies (including gene expression 
profiles, post‑translational modifications and individual gene 
tests) have been conducted, it may be reasonable to recom-
mend melatonin as a potential drug to be considered in the 
treatment of breast cancer.
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